A Phase 4 interventional study of Goserelin and Bicalutamide in Metastatic Prostate Cancer, sponsored by AstraZeneca. Withdrawn at 2 sites in Mexico. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-08-28.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing goserelin in Prostatic Neoplasms — 3 open to participants now, 4 under way, 3 of them phase 3. Goserelin · Prostatic Neoplasms.
Among the 31 studies testing goserelin in Prostatic Neoplasms, this one is the 25th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2004, is one of 4 in phase 4, and was the 6th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →3 of the 31 studies testing goserelin in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Sites in Spain
Ages 18+
Dr. Tamim Niazi · Sites in Canada
Ages 18+ · Men only
By country, each count listing its studies:
Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 16 · Phase 4 4
First in 1987; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 110 across the 29 interventional studies. Of the 22 that completed or were terminated, 5 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 31 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
91 studies in Prostatic Neoplasms by AstraZeneca: 15 open now, 29 under way, 8 of them phase 3. Of 58 finished, 11 (19%) have results posted.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 54th largest by planned enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2004, is one of 4 in phase 4, and was the 8th registered.
AstraZeneca’s Prostatic Neoplasms studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 31 studies testing goserelin in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 91 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Time to progression
Safety
Quality of Life
This study is withdrawn, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Goserelin · Bicalutamide